MYL - Mylan N.V.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
38.99
+0.26 (+0.67%)
At close: 4:00PM EDT

38.95 -0.04 (-0.10%)
After hours: 7:23PM EDT

Stock chart is not supported by your current browser
Previous Close38.73
Open39.20
Bid38.80 x 4000
Ask39.05 x 800
Day's Range38.59 - 39.59
52 Week Range30.69 - 47.82
Volume3,327,954
Avg. Volume3,969,585
Market Cap20.102B
Beta1.37
PE Ratio (TTM)44.97
EPS (TTM)0.87
Earnings DateNov 5, 2018 - Nov 9, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2007-06-27
1y Target Est46.84
Trade prices are not sourced from all markets
  • FDA chief: Looking to regulate nicotine in cigarettes
    Fox Business Videosyesterday

    FDA chief: Looking to regulate nicotine in cigarettes

    U.S. FDA Commissioner Scott Gottlieb, in a wide-ranging interview, said they are looking to regulate nicotine in cigarettes in order to migrate smokers to modified risk products.

  • Mylan and Biocon Announce Positive CHMP Opinion for Fulphila®, Biosimilar Pegfilgrastim
    PR Newswire12 hours ago

    Mylan and Biocon Announce Positive CHMP Opinion for Fulphila®, Biosimilar Pegfilgrastim

    HERTFORDSHIRE, England and PITTSBURGH and BENGALURU, India, Sept. 21, 2018 /PRNewswire/ -- Mylan N.V. (MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Fulphila®, a biosimilar to Amgen's Neulasta® (pegfilgrastim). Data submitted as part of the Marketing Authorization Application included similarity assessment in analytical testing, preclinical and clinical studies that demonstrated biosimilarity to the reference product, Neulasta. The Phase I program in healthy volunteers and Phase III clinical study conducted in breast cancer patients receiving adjuvant and neoadjuvant chemotherapy demonstrated no clinically meaningful differences in terms of pharmacokinetics, pharmacodynamics, safety, efficacy and immunogenicity compared to Neulasta.

  • Mylan Launches Authorized Generic of Ampyra® Tablets
    PR Newswire13 hours ago

    Mylan Launches Authorized Generic of Ampyra® Tablets

    - Mylan's Dalfampridine Extended-Release Tablets, 10 mg, are indicated for patients with multiple sclerosis - HERTFORDSHIRE, England and PITTSBURGH, Sept. 21, 2018 /PRNewswire/ -- Global pharmaceutical ...

  • Mylan and Fujifilm Kyowa Kirin Biologics Receive European Marketing Authorization for Hulio®, Biosimilar Adalimumab
    PR Newswire2 days ago

    Mylan and Fujifilm Kyowa Kirin Biologics Receive European Marketing Authorization for Hulio®, Biosimilar Adalimumab

    HERTFORDSHIRE, England and PITTSBURGH and TOKYO, Sept. 20, 2018 /PRNewswire/ -- Mylan N.V. (MYL) and Fujifilm Kyowa Kirin Biologics Co., Ltd. today announced that the European Commission (EC) has granted marketing authorization for Hulio® (Product Code: FKB327), a biosimilar to AbbVie's Humira® (adalimumab), for all indications. The EC approval of Hulio applies to all 28 European Union (EU) member countries and European Economic Area (EEA) member states of Norway, Iceland and Liechtenstein.

  • Reuters2 days ago

    EU approves fifth copy of AbbVie's $18 bln drug Humira

    Europe has approved a fifth copy of AbbVie's $18-billion-a-year biologic drug Humira – the world's best-selling prescription medicine – ramping up competition among makers of less-expensive biotech drugs. Mylan and Fujifilm Kyowa Kirin Biologics said on Thursday they had won a European Commission green light to market their version of the injectable medicine, known as Hulio.

  • Reuters2 days ago

    Mylan, Fujifilm win EU okay for copy of AbbVie's Humira

    Mylan and Fujifilm Kyowa Kirin Biologics said on Thursday they had won European approval to market a cheaper copy of AbbVie's $18-billion-a-year biologic drug Humira, the world's best-selling prescription ...

  • Theravance, Mylan Report Positive Data on COPD Drug Yupelri
    Zacks3 days ago

    Theravance, Mylan Report Positive Data on COPD Drug Yupelri

    Theravance (TBPH) and partner Mylan post positive data from a late-stage program on COPD Drug, Yupelri.

  • PR Newswire5 days ago

    Theravance Biopharma and Mylan Report New Data from Phase 3 Studies of YUPELRI™ (revefenacin) in Oral Presentation at the European Respiratory Society International Congress

    DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, Sept. 17, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") and Mylan N.V. (MYL) ("Mylan") today announced that positive new data from the companies' Phase 3 clinical program for YUPELRI™ (revefenacin) inhalation solution were featured in an oral presentation at the European Respiratory Society (ERS) International Congress 2018, which is being held in Paris, France on September 15-19, 2018. Presented data showed reductions in the rates of chronic obstructive pulmonary disease (COPD) exacerbations ranging from 15% to 18% in moderate to very severe COPD patients administered once-daily YUPELRI for up to 52 weeks as compared to placebo and tiotropium (Spiriva® HandiHaler®). While the YUPELRI Phase 3 program was not designed or powered to achieve statistical significance on differences in COPD exacerbation rates, researchers were interested in a post-hoc analysis of data from the studies to identify trends in this area.

  • Benzinga5 days ago

    The Week Ahead In Biotech (Sept. 16-22): Conferences, PDUFA Dates, Clinical Trial Results And IPOs

    Biotech were trending mostly sideways in the week ending Sept. 14 after posting weekly gains in the previous two weeks. Notwithstanding the overall muted sentiment, there was some activity in reaction ...

  • See what the IHS Markit Score report has to say about Mylan NV.
    Markit7 days ago

    See what the IHS Markit Score report has to say about Mylan NV.

    Mylan NV NASDAQ/NGS:MYL

  • Acorda (ACOR) Stock Dips, FDA Delays Decision on Inbrija
    Zacks7 days ago

    Acorda (ACOR) Stock Dips, FDA Delays Decision on Inbrija

    The FDA defers decision by three months regarding the NDA of Acorda's (ACOR) Parkinson's disease candidate Inbrija for the treatment of OFF periods.

  • JNJ Stock Up 7% in the Past Month: What Drove the Bulls?
    Market Realist8 days ago

    JNJ Stock Up 7% in the Past Month: What Drove the Bulls?

    On September 12, Johnson & Johnson (JNJ) stock closed at $139.36. That was a 0.61% rise from the previous day’s closing price of $138.51. Currently, JNJ stock is trading above its 50-day moving average of $133.29 and below its 200-day moving average of $127.99.

  • Mylan Adds to Cardiovascular Portfolio With Launch of First Generic of Brevibloc® Injection in Single-Dose Bags
    PR Newswire9 days ago

    Mylan Adds to Cardiovascular Portfolio With Launch of First Generic of Brevibloc® Injection in Single-Dose Bags

    - Esmolol Hydrochloride in Sodium Chloride Injection is used to control heart rate - HERTFORDSHIRE, England and PITTSBURGH , Sept. 13, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: ...

  • Johnson & Johnson: Analyst Recommendations and Target Price
    Market Realist9 days ago

    Johnson & Johnson: Analyst Recommendations and Target Price

    Johnson & Johnson (JNJ) is one of the major healthcare companies in the world. It operates through its pharmaceuticals, medical devices, and consumer business segments. Although its pharmaceutical business generates most of its sales, medical devices and consumer business include a number of leading brands in their respective market spaces.

  • PR Newswire10 days ago

    Theravance Biopharma and Mylan to Report New Data from Phase 3 Studies of YUPELRI™ (revefenacin) in Oral Presentation at European Respiratory Society International Congress 2018

    DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, Sept. 11, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") and Mylan N.V. (MYL) ("Mylan") today announced that new data from the Phase 3 YUPELRI™ (revefenacin) inhalation solution clinical program will be featured in an oral presentation at the European Respiratory Society (ERS) International Congress 2018, being held in Paris, France on September 15-19, 2018. The presented data will highlight chronic obstructive pulmonary disease (COPD) exacerbation rates observed in the Phase 3 clinical program of YUPELRI in patients with moderate to very severe COPD.

  • Acorda Gets Unfavorable Court Ruling for Ampyra, Stock Down
    Zacks10 days ago

    Acorda Gets Unfavorable Court Ruling for Ampyra, Stock Down

    Acorda Therapeutics' (ACOR) stock slumps after a Federal Circuit Court rules against its appeal to protect patents pertaining to its key multiple sclerosis drug, Ampyra

  • New Strong Sell Stocks for September 10th
    Zacks12 days ago

    New Strong Sell Stocks for September 10th

    Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

  • Why Is Mylan (MYL) Up 6.3% Since Last Earnings Report?
    Zacks14 days ago

    Why Is Mylan (MYL) Up 6.3% Since Last Earnings Report?

    Mylan (MYL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Investor's Business Daily15 days ago

    These Hospital Systems Are Aiming To Undercut Biotechs, Drugmakers

    Generic-drug and biotech stocks plunged into the red Thursday after several leading hospital groups launched a nonprofit to undercut drug prices.

  • Reuters16 days ago

    Walgreens to supply Kaleo's allergy shots as EpiPen shortage drags

    U.S. drugstore chain Walgreens Boots Alliance Inc said on Thursday emergency allergy shots from Kaleo will be available in its stores, the latest effort to address shortages of the lifesaving treatment during the back-to-school season. There has been an acute shortage of Mylan's EpiPen, which dominates the allergy market, with the health regulator last month extending the expiration date of specific lots of the treatment. In August, Mylan issued a warning that the devices may not always be available.

  • Mylan Suffers Several Setbacks: What's in Store in 2H18?
    Zacks18 days ago

    Mylan Suffers Several Setbacks: What's in Store in 2H18?

    Mounting competition and recent setbacks cast a pall over Mylan's (MYL) near-term performance.

  • ETF Trends21 days ago

    Biotech Fund Flows, Including ETF Activity, Remain a Driver to Watch

    The biotech sector performed well in August, with the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB) up almost 3.5% this week alone. Research by Raymond James indicates that in just the past week, biotech ...

  • The Wall Street Journal26 days ago

    EpiPen Shortage Hits Back-to-School Season

    Parents are scrambling to find pharmacies carrying EpiPens for the new school year as regulators and the drug’s manufacturer struggle to abate a continuing global shortage of the lifesaving devices. EpiPens, the emergency epinephrine treatment for allergic reactions, have been in short supply since at least May, when the U.S. Food and Drug Administration first declared a shortage. A rival epinephrine injector product, a generic version of Adrenaclick made by Amneal Pharmaceuticals Inc., is also in short supply, according to the FDA.

  • There’s an EpiPen shortage—and parents fear for their allergic children headed back to school
    MarketWatch27 days ago

    There’s an EpiPen shortage—and parents fear for their allergic children headed back to school

    Only after calling between eight and 10 pharmacies in her New Jersey area was Wachtler able to find a two-pack of the generic EpiPen—and it was the pharmacy’s last box. Mylan’s (MYL) brand-name EpiPen and the authorized generic, two widely used allergic reaction treatments, as well as Amneal Pharmaceuticals’ (AMRX) generic auto-injector Adrenaclick were added to the Food and Drug Administration’s drug shortage list in May.

  • MarketWatch28 days ago

    Popular health-care ETF finishes at an all-time high as stock market rallies

    A popular exchange-traded fund that tracks the health-care sector finished at its highest level in its history on Friday. The Health Care Select Sector SPDR ETF (XLV) advanced by 0.4% to reach 91.82, representing its highest level since the vehicle was created in 1998 to match the S&P 500 index's (SPX) health-care sector. The record for the health-care ETF underscores a rally on Wall Street in late August that has the small-capitalization Russell 2000 index (RUT) the Nasdaq Composite Index (COMP) and the S&P 500 putting records of their own.